🇺🇸 New Drug Application for “K-911” Targeting Patients with Glaucoma and Ocular Hypertension Accepted for Filing in the U.S., Food and Drug Administration

by

🇺🇸

NAGOYA, Japan, Aug. 27, 2026 /PRNewswire/ — Kowa Company, Ltd. (hereafter referred to as “Kowa”) is developing K-911 for the indication of reducing intraocular pressure (IOP) in patients with glaucoma or ocular hypertension through its affiliated company engaged in pharmaceutical…

Source: prnewswire

Country: United States